Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Thursday

Tenax Therapeutics (NASDAQ:TENX) is expected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Tenax Therapeutics to post earnings of ($0.51) per share for the quarter.

Tenax Therapeutics Trading Down 5.6 %

Shares of TENX stock opened at $6.20 on Tuesday. The firm’s fifty day moving average price is $6.44 and its two-hundred day moving average price is $5.37. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89.

Analyst Ratings Changes

TENX has been the topic of several analyst reports. Leerink Partners set a $20.00 target price on Tenax Therapeutics in a report on Monday, March 10th. StockNews.com assumed coverage on Tenax Therapeutics in a research report on Friday. They set a “sell” rating on the stock. Finally, William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $18.00.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.